Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preventive HIPEC plus perioperative FLOT versus perioperative FLOT alone in resectable diffuse gastric or gastroesophageal junction adenocarcinoma
2017-003832-35Phase 3Active
- Sponsor
- Institute of Cancer Research
- Start
- May 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel, oxaliplatin, fluorouracil, folinic acid and cisplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Institute of Cancer Research. Primary endpoint: Progression-free survival / disease-free survival. Started May 2020; status: active.
02
Drugs
docetaxeloxaliplatinfluorouracilfolinic acidcisplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2017-003832-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003832-35.